By Brendan Pierson (Reuters) -Abbott and Reckitt’s unit Mead Johnson are not responsible for a young boy’s debilitating intestinal disease,...
Read moreInvesting.com — Barclays analysts suggested in a note Friday that while markets have largely priced in a Trump victory, uncertainty remains...
Read more(Reuters) – Cboe Global Markets (NYSE:CBOE) reported a rise in third-quarter profit on Friday, driven by strong options trading as...
Read more(Reuters) – U.S. stock index futures rose on Friday, buoyed after upbeat earnings from Amazon offset a tech-led selloff in...
Read moreBlue Owl Capital Inc. (ticker: OWL) has announced strong third-quarter results for 2024, with significant increases in management fees and...
Read moreEMCOR Group, a leading provider of mechanical and electrical construction services, reported a significant increase in its third-quarter revenues for...
Read moreComstock Resources (NYSE: NYSE:CRK) presented its third-quarter 2024 earnings on October 31, 2024, with a focus on its strategic advancements...
Read moreKontoor Brands (NYSE: NYSE:KTB), the apparel company behind popular brands such as Wrangler and Lee, reported robust third-quarter results for...
Read moreBNP Paribas (OTC:BNPQY) (BNP.PA) has announced a robust performance for the third quarter of 2024, with a net income group...
Read moreDuring Broadstone Net Lease’s (NYSE: BNL) Third Quarter 2024 Earnings Conference Call, CEO John Moragne provided an update on the...
Read moreDisclaimer: WallStreetJedi.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.